Nirmatrelvir 150 And Ritonavir 100

Composition

• Nirmatrelvir – 150 mg (2 tablets per dose)
• Ritonavir – 100 mg (1 tablet per dose)
• Pack includes 30 tablets (5-day treatment course)

Indication

Indicated for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years and older, weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death.

Dosage & Administration

• Standard Dose: 2 tablets of Nirmatrelvir (150 mg each) + 1 tablet of Ritonavir (100 mg) twice daily for 5 days
• Begin treatment as soon as possible after diagnosis and within 5 days of symptom onset
• Swallow tablets whole; do not crush or chew

Key Benefits

• Reduces hospitalization and death risk in high-risk COVID-19 patients
• Oral administration — no need for injections
• Short 5-day treatment course
• Authorized by regulatory bodies under Emergency Use Authorization (EUA)

Precautions & Warnings

• Not recommended for patients with severe kidney or liver impairment
• May interact with other medications — consult your doctor
• Not authorized for pre- or post-exposure prophylaxis
• Use only under prescription and medical supervision

Possible Side Effects

• Altered taste (dysgeusia)
• Diarrhea
• High blood pressure
• Muscle aches
• Drug interactions (with blood thinners, anticonvulsants, statins, etc.)

FAQs

1. What is Nirmatrelvir and Ritonavir used for?

This combination is used to treat mild-to-moderate COVID-19 in patients at high risk of developing severe illness.

2. Is this the same as Paxlovid?

Yes, Paxlovid is the branded version containing Nirmatrelvir and Ritonavir in the same dosages.

3. When should I start treatment?

It must be started within 5 days of symptom onset and after a confirmed COVID-19 diagnosis.

4. Can I take it with other medications?

Ritonavir may interact with many drugs. Always inform your healthcare provider about all medications you’re taking.

5. Is it safe for children?

It is approved for use in children aged 12 years and older weighing at least 40 kg, under medical supervision.